Supplementary Materials

Supplementary Material for:

Rational design of small molecules as vaccine adjuvants

Tom Y.-H. Wu, Manmohan Singh, Andrew T. Miller, Ennio De Gregorio, Francesco Doro, Ugo D'Oro, David A. G. Skibinski, M. Lamine Mbow, Simone Bufali, Ann E. Herman, Alex Cortez, Yongkai Li, Bishnu P. Nayak, Elaine Tritto, Christophe M. Filippi, Gillis R. Otten, Luis A. Brito, Elisabetta Monaci, Chun Li, Susanna Aprea, Sarah Valentini, Samuele Calabró, Donatello Laera, Brunella Brunelli, Elena Caproni, Padma Malyala, Rekha G. Panchal, Travis K. Warren, Sina Bavari, Derek T. O'Hagan,* Michael P. Cooke,* Nicholas M. Valiante*

*Corresponding author. E-mail: nicholas.valiante{at}novartis.com (N.M.V.); mcooke{at}gnf.org (M.P.C.); derek.ohagan{at}novartis.com (D.T.O.)

Published 19 November 2014, Sci. Transl. Med. 6, 263ra160 (2014)
DOI: 10.1126/scitranslmed.3009980

This PDF file includes:

  • Fig. S1. Adjuvants by design.
  • Fig. S2. Cellular activation in draining lymph nodes by first-generation SMIPs.
  • Fig. S3. First-generation SMIPs localized by physical chemical properties.
  • Fig. S4. 3MenB/Al(OH)3/SMIP formulation characterization.
  • Fig. S5. Rapid priming of TH cells by Al(OH)3-adsorbed SMIPs.
  • Table S1. First-generation SMIP in vitro activity.
  • Table S2. Second-generation SMIP in vitro activity.
  • Table S3. SMIP in vitro cytokine profile.
  • Flow cytometry gating strategy and isotype controls (Fig. 4B)
  • Source data Fig. 1
  • Source data Fig. 2
  • Source data Fig. 3
  • Source data Fig. 4
  • Source data Fig. 5
  • Source data Fig. 6

[Download PDF]